Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/58043
Title: Prognostic value of albi score and lymphocyte-associated inflammation markers in advanced hepatocellular carcinoma: a single centre retrospective cross-sectional study
Authors: Ozdemir, Melek
Dogu, Gamze Gokoz
Taskoylu, Burcu Yapar
Demiray, Atike Gökçen
Çakan Demirel, Burçin
Doğan, Tolga
Güçlü Kantar, Taliha
Yaren, Arzu
Degirmencioglu, Serkan
Tas, Semra
Yildiz, Bedriye Acikgoz
Ozel, Gamze Serin
Keywords: HCC
ALBI score
lymphocyte-associated inflammatory marker
ALRI
survival
Cancer
Cytokines
Publisher: Galenos Publ House
Abstract: Aim According to the information obtained from the World Health Organization database, the incidence of hepatocellular carcinoma (HCC) in Turkey increased by 17.78% between the years of 2018 and 2020. In this study, we investigated the prognostic value of albumin-bilirubin (ALBI) score and lymphocyte-associated inflammation markers on overall survival (OS) and progression-free survival (PFS) in advanced hepatocellular carcinoma. Materials and Methods Data of 141 patients with advanced HCC were included in this study. ALBI score and lymphocyte-associated inflammatory marker were calculated. As a result, the prognostic significance of these tests for survival were evaluated. Results The median age was 65 years (min: 26-max: 88). There were 58 (41.1%) hepatitis B virus (HBV) positive, 20 (14.2%) hepatitis C (HCV) positive and 63 (44.7%) patients with no history of hepatitis. Cut-off values of ALBI score and lymphocyte-associated inflammation markers were found by receiver operating characteristic analysis. ALBI (p<0.001), aspartate aminotransferase-to-lymphocyte ratio (ALRI) (p<0.001), prognostic nutritional index (PNI) (p=0.030), hemoglobin, albumin, lymphocyte, and platelet score (HALP) (p=0.003) scores were significantly associated with survival. In multivariate analysis, being >= 65 years old [hazard ratios (HR): 2.13; 95% confidence interval (CI): 1.44-3.17; p<0.001], ALRI >= 30.79 (HR: 2.14; 95% CI: 1.20-3.82; p=0.009) predicted an increased risk of death and ALBI >=-2.54 (HR: 0.44, 95% CI: 0.29-0.69; p<0.001) predicted a decreased risk of death. Being >= 65 years old (HR: 174, 95% CI: 1.18-2.56; p=0.005) increased the risk of progression. Conclusion This study supports the statistically significant association of ALBI score and lymphocyte-associated inflammation markers (ALRI, PNI, HALP) with OS and PFS in advanced HCC patients. It is thought that this study will contribute to the literature and clinical practice.
URI: https://doi.org/10.4274/nkmj.galenos.2024.93898
https://hdl.handle.net/11499/58043
ISSN: 2587-0262
Appears in Collections:Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
155-162.pdf1.4 MBAdobe PDFView/Open
Show full item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.